capmatinib sold brand name tabrecta anticancer medication used treatment metastatic nonsmall cell lung cancer whose tumors mutation leads exon skipping met gene codes membrane receptor common adverse reactions peripheral edema nausea fatigue vomiting dyspnea decreased nonsmall cell lung cancer disease malignant cancer cells form tissues common type lung cancer lung carcinomas falling nonsmall cell nonsmall cell lung cancer occurs healthy cells become abnormal grow one danger form cancer theres high likelihood cancer cells spread lungs organs body cancer metastasis consists sequential series events met exon skipping recognized critical event metastasis mutations leading met exon skipping found people lung capmatinib approved medical use united states may capmatinib first therapy approved us food drug administration fda treat nonsmall cell lung cancer specific mutations lead mesenchymalepithelial transition met exon capmatinib kinase inhibitor indicated treatment adults metastatic nonsmall cell lung cancer whose tumors mutation leads mesenchymalepithelial transition met exon capmatinib cause interstitial lung disease group lung conditions causes scarring lung tissues pneumonitis inflammation lung tissue hepatotoxicity damage liver cells photosensitivity embryofetal based clear positive signal phototoxicity early laboratory studies cells people may sensitive sunlight advised take precautions cover skin use sunscreen tan taking capmatinib may cause harm developing fetus newborn substance inhibits tyrosine kinase plays role embryonic development organogenesis wound healing also development cancer capmatinib approved medical use united states may along foundationone cdx assay companion diagnostic efficacy demonstrated geometry trial multicenter nonrandomized openlabel multicohort study enrolling participants metastatic nonsmall cell lung cancer confirmed met exon participants previously treated cancer participants received capmatinib mg orally twice daily disease progression unacceptable efficacy based results trial conducted sites united states austria belgium france germany israel italy japan korea lebanon mexico netherlands norway russia singapore sweden switzerland spain taiwan major efficacy outcome measure overall response rate orr reflects percentage participants certain amount tumor additional efficacy outcome measure duration response efficacy population included participants never undergone treatment nonsmall cell lung cancer previously treated orr participants complete response partial orr participants partial responding participants never undergone treatment nonsmall cell lung cancer duration response lasting months longer compared responding participants previously us food drug administration fda processed application accelerated approval program granted application capmatinib priority review orphan drug breakthrough therapy granted approval tabrecta novartis pharmaceuticals april committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product tabrecta intended treatment patients advanced nonsmall cell lung cancer harboring alterations leading mesenchymalepithelial transition factor gene exon applicant medicinal product novartis europharm capmatinib approved medical use european union september httpsenwikipediaorgwikicapmatinib